BioCentury
ARTICLE | Emerging Company Profile

Clear for Landos

How Landos’ first-in-class LANCL2 agonist could improve upon existing IBD drugs

April 20, 2018 10:56 PM UTC

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC).

TNF alpha inhibitors are standard of care for moderate to severe CD and UC, but they require IV infusion and only work in 40-60% of patients. Furthermore, systemic immunosuppression due to TNF alpha inhibition can lead to significant side effects including infection and cancer, said CEO Josep Bassaganya-Riera...